The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 2, 2011, Pages 161-162

  Wong, David ^b   Joussen, Antonia M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti VEGF

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EDITORIAL; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; MORTALITY; OFF LABEL DRUG USE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; SOCIAL STATUS; STROKE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CAUSE OF DEATH; HEMORRHAGE; HUMANS; MACULAR DEGENERATION; MYOCARDIAL INFARCTION; PHOTOCHEMOTHERAPY; RISK FACTORS; STROKE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952450499     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1603-7     Document Type: Editorial

References (3)

1. NICE Technology Appraisal 155, Issued August 2008. Pegaptanib and ranibizumab for the treatment of age-related macular degeneration.
2. http://news.xinhuanet.com/english2010/china/2010-09/15/c-13495920.htm accessed on 9 December 2010
3. LH Curtis BG Hammill KA Schulman SW Cousins 2010 Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Arch Ophthalmol 128 10 1273 1279 10.1001/archophthalmol.2010.223 20937996